Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct093
Abstract: Background: In an open-label, phase Ib dose-finding and dose-expansion study in pts with aRCC, AXI+PEMBRO was tolerable; objective response rate (ORR) was 73.1%, and median progression free survival (mPFS) was 20.9 months (Lancet Oncol. 2018;19:405-15).… read more here.
Keywords: combination pembrolizumab; axitinib combination; pembro; axi pembro ... See more keywords